image
Healthcare - Medical - Devices - NYSE - US
$ 104.84
-2.33 %
$ 20.9 B
Market Cap
23.67
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ZBH stock under the worst case scenario is HIDDEN Compared to the current market price of 105 USD, Zimmer Biomet Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ZBH stock under the base case scenario is HIDDEN Compared to the current market price of 105 USD, Zimmer Biomet Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one ZBH stock under the best case scenario is HIDDEN Compared to the current market price of 105 USD, Zimmer Biomet Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ZBH

image
$114.0$114.0$112.0$112.0$110.0$110.0$108.0$108.0$106.0$106.0$104.0$104.0$102.0$102.0$100.0$100.0$98.0$98.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
7.68 B REVENUE
3.85%
1.29 B OPERATING INCOME
0.63%
452 M NET INCOME
-55.82%
1.5 B OPERATING CASH FLOW
-5.20%
-888 M INVESTING CASH FLOW
-14.02%
-484 M FINANCING CASH FLOW
36.54%
2.02 B REVENUE
10.91%
389 M OPERATING INCOME
39.18%
240 M NET INCOME
-3.65%
506 M OPERATING CASH FLOW
27.95%
-291 M INVESTING CASH FLOW
-87.99%
-241 M FINANCING CASH FLOW
-136.11%
Balance Sheet Zimmer Biomet Holdings, Inc.
image
Current Assets 4.67 B
Cash & Short-Term Investments 526 M
Receivables 1.48 B
Other Current Assets 2.67 B
Non-Current Assets 16.7 B
Long-Term Investments 0
PP&E 2.05 B
Other Non-Current Assets 14.6 B
6.93 %12.47 %9.59 %68.55 %Total Assets$21.4b
Current Liabilities 2.45 B
Accounts Payable 195 M
Short-Term Debt 863 M
Other Current Liabilities 1.39 B
Non-Current Liabilities 6.44 B
Long-Term Debt 5.34 B
Other Non-Current Liabilities 1.1 B
9.71 %15.67 %60.09 %12.34 %Total Liabilities$8.9b
EFFICIENCY
Earnings Waterfall Zimmer Biomet Holdings, Inc.
image
Revenue 7.68 B
Cost Of Revenue 2.19 B
Gross Profit 5.49 B
Operating Expenses 4.2 B
Operating Income 1.29 B
Other Expenses 833 M
Net Income 452 M
8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b008b(2b)5b(4b)1b(833m)452mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
71.46% GROSS MARGIN
71.46%
16.74% OPERATING MARGIN
16.74%
11.77% NET MARGIN
11.77%
7.25% ROE
7.25%
4.23% ROA
4.23%
5.68% ROIC
5.68%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Zimmer Biomet Holdings, Inc.
image
2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 452 M
Depreciation & Amortization 996 M
Capital Expenditures -357 M
Stock-Based Compensation 101 M
Change in Working Capital 0
Others -418 M
Free Cash Flow 1.14 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Zimmer Biomet Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for ZBH of $128 , with forecasts ranging from a low of $110 to a high of $150 .
ZBH Lowest Price Target Wall Street Target
110 USD 4.92%
ZBH Average Price Target Wall Street Target
128 USD 22.22%
ZBH Highest Price Target Wall Street Target
150 USD 43.08%
Price
Max Price Target
Min Price Target
Average Price Target
1501501401401301301201201101101001009090May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.22% DIVIDEND YIELD
0.24 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.000001.000000.900000.900000.800000.800000.700000.700000.600000.600000.500000.500000.400000.400000.300000.300000.200000.200000.100000.100000.000000.000000.213590.233010.233010.233010.233010.233010.233010.240.240.240.240.213590.233010.233010.233010.233010.233010.233010.240.240.240.213590.233010.233010.233010.233010.233010.233010.240.240.213590.850.233010.930.233010.930.233010.930.233010.930.233010.930.233010.930.240.960.240.960.480.242015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Zimmer Biomet Holdings, Inc.
image
Sold
0-3 MONTHS
151 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.47 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Paragon will receive $13.00 in cash as well as a non-tradeable contingent value right, entitling the holder to receive up to $1.00 per share in cash if certain revenue mileston. businesswire.com - 2 weeks ago
Zimmer Biomet Receives CE Mark Approval for RibFix Advantage® Fixation System Expanding Thoracic Portfolio WARSAW, Ind., and ZUG, Switzerland , April 1, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today announced its RibFix Advantage® Fixation System has received CE Mark certification – the first CE Mark for an intrathoracic rib fixation system. prnewswire.com - 2 weeks ago
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025 Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025. zacks.com - 3 weeks ago
Should You Consider Retaining ZBH Stock in Your Portfolio Now? Zimmer Biomet's robust Knee business appears promising. However, a dull macroeconomic condition adds to the worry. zacks.com - 3 weeks ago
Zimmer Biomet Focuses on Innovation Amid Growing Competition Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention. zacks.com - 1 month ago
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space. zacks.com - 1 month ago
Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE: ZBH) (“Zimmer Biomet”). The expiration of the waiting period under the. businesswire.com - 1 month ago
Zimmer Biomet Highlights Diverse Portfolio of Orthopedic & Musculoskeletal Innovations at AAOS 2025 Annual Meeting Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ZBX™ Ambulatory Surgery Center Solutions WARSAW, Ind., March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting its diverse portfolio of orthopedic and musculoskeletal innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting being held March 10-14 in San Diego. prnewswire.com - 1 month ago
Zimmer Biomet Receives FDA Clearance for Persona® Revision SoluTion™ Femur A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® Revision SoluTion™ Femur, a revision knee implant component offering an alternative for patients with sensitivities to certain metals. prnewswire.com - 1 month ago
Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. prnewswire.com - 1 month ago
Zimmer Biomet Launches You'll Be Back Campaign with Chief Movement Officer Arnold Schwarzenegger Schwarzenegger Invites People Living with Joint Pain to Join New Online Community, Share Their Stories and Connect with a Qualified Physician WARSAW, Ind. , Feb. 26, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the launch of the  You'll Be Back  campaign with the Company's Chief Movement Officer, Arnold Schwarzenegger. prnewswire.com - 1 month ago
ZBH Stock Hurt by Margin Concerns and Difficult Solvency Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations. zacks.com - 1 month ago
8. Profile Summary

Zimmer Biomet Holdings, Inc. ZBH

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 20.9 B
Dividend Yield 0.22%
Description Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Contact 345 East Main Street, Warsaw, IN, 46580 https://www.zimmerbiomet.com
IPO Date July 25, 2001
Employees 17000
Officers Ms. Angela Main Senior Vice President, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific Mr. Ivan Tornos President, Chief Executive Officer & Director Mr. Suketu P. Upadhyay Chief Financial Officer and Executive Vice President of Finance, Operations & Supply Chain Mr. David M. DeMartino Senior Vice President of Investor Relations Mr. Sang Yi Group President of Asia Pacific Mr. Paul A. Stellato Vice President, Controller & Chief Accounting Officer Mr. Chad F. Phipps J.D. Senior Vice President, General Counsel & Secretary Mr. Wilfred van Zuilen Group President of Europe, Middle East & Africa Ms. Kristen Cardillo Senior Vice President & Chief Communications Officer Mr. Shaun Braun Senior Vice President & Chief Information and Technology Officer